
GlaxoSmithKline has decided not to sell off several of its ageing brands in the face of continuing business problems. The …

GlaxoSmithKline is looking to make more than £7 billion by selling off its ageing portfolio of established drugs. This is …
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
Phoenix Labs acquires Kent Pharma
Astoriom acquires Sampled’s UK stability storage operations
Alcami appoints Will Isom to lead laboratory services sales

